PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Vorkas, P. A.
Agelaki, S.
Poumpouridou, N.
Kroupis, C.
Mavroudis, D.
Stathopoulos, E.
Georgoulias, V
Liandou, E. S.
机构：
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：599S / 599S
页数：1
相关论文
共 50 条
  • [21] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    MEDICINE, 2024, 103 (24) : e38508
  • [22] Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer.
    Yu, Yunfang
    Wang, Ying
    Chen, Kai
    Fu, Tuping
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [24] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
    Lee, Yong-Pyo
    Lee, Min-Sang
    Kim, HongSik
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
  • [25] Targeting the PI3K pathway in HER2-positive gastric cancer
    Toomey, S.
    Farrelly, A. M.
    Mezynski, M. J.
    Carr, A.
    Armstrong, P.
    Mcauley, J.
    Fay, J.
    Kay, E. W.
    Cremona, M.
    Holohan, C.
    Keegan, N. M.
    Elamin, Y.
    Rafee, S.
    Hennessy, B. T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E142 - E142
  • [26] Inhibition of the PI3K pathway in HER2-positive gastric cancer
    Toomey, S.
    Mezynski, M. J.
    Farrelly, A.
    Armstrong, P.
    McAuley, J.
    Holohan, C.
    Elamin, Y. Y.
    Rafee, S.
    Workman, J.
    Cremona, M.
    Grogan, L.
    Breathnach, O. S.
    Morris, P. G.
    Fay, J.
    Kay, E.
    Hennessy, B. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [28] Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
    Gullo, G.
    Zuradelli, M.
    Sclafani, F.
    Santoro, A.
    Crown, J.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2204 - 2205
  • [29] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [30] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
12345